Skip to content
Sodium stibogluconate
Sodium stibogluconate is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
P: Antiparasitic products, insecticides and repellents
— P01: Antiprotozoals
— P01C: Agents against leishmaniasis and trypanosomiasis
— P01CB: Antimony compounds for treatment of leishmaniasis and trypanosomiasis
— P01CB02: Sodium stibogluconate
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Cutaneous leishmaniasisD016773B55.1—21137
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Visceral leishmaniasisD007898B55.0——2—13
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
LeishmaniasisD007896EFO_0005044B5512——13
Myelodysplastic syndromesD009190D4611———2
Wound healingD014945GO_0042060—1———1
Myeloid leukemia acuteD015470C92.0—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C802————2
MelanomaD0085451————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Mucocutaneous leishmaniasisD007897EFO_0007379B55.2————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameSODIUM STIBOGLUCONATE
INNsodium stibogluconate
Description
Sodium stibogluconate, sold under the brand name Pentostam among others, is a medication used to treat leishmaniasis. This includes leishmaniasis of the cutaneous, visceral, and mucosal types. Some combination of miltefosine, paramycin and liposomal amphotericin B, however, may be recommended due to issues with resistance. It is given by injection.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
O.O.O.O.O.O.O.O.O.O=C([O-])[C@@H]1O[Sb](=O)(O[Sb]2(=O)O[C@@H](C(=O)[O-])[C@@H](O)[C@@H]([C@H](O)CO)O2)O[C@H]([C@H](O)C[O-])[C@@H]1O.[Na+].[Na+].[Na+]
Identifiers
PDB—
CAS-ID16037-91-5
RxCUI—
ChEMBL IDCHEMBL2079699
ChEBI ID—
PubChem CID70682647
DrugBankDB05630
UNII IDV083S0159D (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 2,179 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
26 adverse events reported
View more details